- Home
- DFIN vs MNKD Comparison
DFIN vs MNKD Comparison
Compare DFIN & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DFIN
- MNKD
- Stock Information
- Founded
- DFIN 1983
- MNKD 1991
- Country
- DFIN United States
- MNKD United States
- Employees
- DFIN N/A
- MNKD N/A
- Industry
- DFIN Other Consumer Services
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- DFIN Consumer Discretionary
- MNKD Health Care
- Exchange
- DFIN Nasdaq
- MNKD Nasdaq
- Market Cap
- DFIN 1.9B
- MNKD 1.9B
- IPO Year
- DFIN N/A
- MNKD 2004
- Fundamental
- Price
- DFIN $65.00
- MNKD $6.08
- Analyst Decision
- DFIN Strong Buy
- MNKD Buy
- Analyst Count
- DFIN 3
- MNKD 6
- Target Price
- DFIN $76.33
- MNKD $8.92
- AVG Volume (30 Days)
- DFIN 231.7K
- MNKD 2.5M
- Earning Date
- DFIN 02-18-2025
- MNKD 02-25-2025
- Dividend Yield
- DFIN N/A
- MNKD N/A
- EPS Growth
- DFIN 18.18
- MNKD N/A
- EPS
- DFIN 3.18
- MNKD 0.08
- Revenue
- DFIN $802,100,000.00
- MNKD $267,200,000.00
- Revenue This Year
- DFIN $1.69
- MNKD $45.45
- Revenue Next Year
- DFIN $4.17
- MNKD $16.45
- P/E Ratio
- DFIN $20.67
- MNKD $76.18
- Revenue Growth
- DFIN 1.74
- MNKD 51.35
- 52 Week Low
- DFIN $56.02
- MNKD $3.17
- 52 Week High
- DFIN $71.01
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- DFIN 66.56
- MNKD 38.31
- Support Level
- DFIN $60.79
- MNKD $5.79
- Resistance Level
- DFIN $66.23
- MNKD $6.11
- Average True Range (ATR)
- DFIN 1.78
- MNKD 0.19
- MACD
- DFIN 0.63
- MNKD -0.03
- Stochastic Oscillator
- DFIN 93.14
- MNKD 25.28
About DFIN Donnelley Financial Solutions Inc.
Donnelley Financial Solutions Inc is a global risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( US), Europe, Asia, Canada, and others, of which the US accounts for the vast majority of its total revenue.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.